Abstract: The invention describes HLA class II binding peptides encoded by the SSX-2 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the SSX-2 gene.
Type:
Grant
Filed:
July 21, 2004
Date of Patent:
March 22, 2011
Assignee:
Ludwig Institute for Cancer Research Ltd.
Abstract: Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in breast, gastric and prostate cancer cells using antisera from cancer patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with cancer. The invention provides, inter alia, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided.
Type:
Grant
Filed:
October 20, 2008
Date of Patent:
February 1, 2011
Assignee:
Ludwig Institute for Cancer Research Ltd.
Abstract: The invention relates to the identification of astrocytoma markers, astrocytoma stem cells and markers of such stem cells, and diagnostic, prognostic and therapeutic methods based on an understanding of the markers and cells.
Type:
Application
Filed:
April 25, 2008
Publication date:
December 23, 2010
Applicant:
LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.
Inventors:
Otavia L. Caballero, Suely Kazue Nagahashi Marie, Sueli Mieko Oba Shinjo, Oswaldo Keith Okamoto
Abstract: The invention provides methods, compositions and kits for inducing and/or enhancing an immune response in a subject. The invention in some aspects includes polypeptide and nucleic acid molecules that induce and/or enhance an immune response. In some aspects of the invention, the polypeptide and/or nucleic acid molecules of the invention are useful to induce and/or enhance an immune response in a subject who has or is suspected of having cancer.
Type:
Grant
Filed:
September 9, 2004
Date of Patent:
September 28, 2010
Assignees:
Ludwig Institute for Cancer Research Ltd., Chancelors Masters and Scholars of the University of Oxford
Abstract: Methods for inhibiting angiogenesis comprising administering tissue-plasminogen activator (tPA) inhibitors, and pharmaceutical compositions suitable for the methods comprising the tPA inhibitors. Also provided are methods for stimulating angiogenesis comprising administering tPA to a patient in need thereof, and pharmaceutical compositions comprising an effective amount of tPA for the methods of stimulation. The present invention discloses that tPA is a specific PDGF-C activating protease, and that the CUB-domains in PDGF-CC directly interact with the protease, are required for efficient proteolysis, and released CUB-domains are tPA inhibitors. Preferably, the method and compositions of the present invention are used for simultaneously stimulating, or simultaneously inhibiting, thrombolysis and angiogenesis.
Type:
Application
Filed:
January 6, 2010
Publication date:
September 2, 2010
Applicant:
Ludwig Institute for Cancer Research Ltd.
Inventors:
Linda Fredriksson, Hong Li, Christina Fieber, Xuri Li, Ulf Eriksson
Abstract: The present invention relates generally to growth factor receptor epitope peptides, particularly EGF family receptor epitope peptides. The invention also relates to the use of the receptor peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against the receptor peptides. Methods for generating an immune response and for treatment of tumors and cancer are also provided.
Type:
Grant
Filed:
February 17, 2005
Date of Patent:
August 3, 2010
Assignees:
Ludwig Institute for Cancer Research Ltd., Commonwealth Scientific & Industrial Research Organization, Massachusetts Institute for Technology
Inventors:
Terrance Grant Johns, Andrew Mark Scott, Antony Wilks Burgess, Lloyd J. Old, Timothy E. Adams, K. Dane Wittrup, Ginger Chao, Peter Anthony Hoyne
Abstract: The invention relates to sarcoma-associated antigens and the nucleic acid molecules that encode them. The invention further relates to the use of the nucleic acid molecules, polypeptides and fragments thereof associated with sarcoma in methods and compositions for the diagnosis and treatment of diseases, such as cancer. More specifically, the invention relates to the discovery of a novel cancer/testis (CT) antigen, NY-SAR-35.
Type:
Application
Filed:
January 6, 2010
Publication date:
July 8, 2010
Applicant:
Ludwig Institute for Cancer Research Ltd.
Inventors:
Matthew J. Scanlan, Cynthia H. Scanlan, Sang-Yull Lee, Lloyd J. Old
Abstract: The invention describes the LAGE-1 tumor associated gene, including fragments, allelic variants and splice variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a LAGE-1 gene product.
Type:
Application
Filed:
July 14, 2009
Publication date:
November 5, 2009
Applicant:
Ludwig Institute for Cancer Research Ltd.
Inventors:
Bernard Lethe, Sophie Lucas, Charles De Smet, Daniele Godelaine, Thierry Boon-Falleur
Abstract: Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in breast, gastric and prostate cancer cells using antisera from cancer patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with cancer. The invention provides, inter alia, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided.
Type:
Application
Filed:
October 20, 2008
Publication date:
September 24, 2009
Applicant:
Ludwig Institute for Cancer Research Ltd.
Abstract: Polypeptides comprising an unbroken sequence of amino acids from SEQ. ID. NO. 1 or 2, with an ability to complex with a major histocompatibility complex molecule type HLA-A2, and preferably HLA-A2.1.
Type:
Application
Filed:
February 3, 2009
Publication date:
August 20, 2009
Applicant:
Ludwig Institute for Cancer Research Ltd.
Inventors:
Lan-Qing Huang, Aline Van Pel, Francis Brasseur, Etienne De Plaen, Thierry Boon-Falleur
Abstract: The invention describes the LAGE-1 tumor associated gene, including fragments, allelic variants and splice variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a LAGE-1 gene product.
Type:
Grant
Filed:
June 25, 2004
Date of Patent:
July 21, 2009
Assignee:
Ludwig Institute for Cancer Research Ltd.
Abstract: The invention relates to stimulation of immune responses against antigen(s) and overcoming regulatory T cell suppression of such immune responses against antigen(s).
Type:
Application
Filed:
October 31, 2008
Publication date:
May 28, 2009
Applicant:
Ludwig Institute for Cancer Research Ltd.
Abstract: The invention describes HLA class II binding peptides encoded by the SSX-2 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating to the peptides. The peptides stimulate the activity and proliferation of CD4+T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the SSX-2 gene.
Type:
Application
Filed:
September 19, 2008
Publication date:
April 16, 2009
Applicant:
Ludwig Institute for Cancer Research Ltd.